Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ANGO logo ANGO
Upturn stock ratingUpturn stock rating
ANGO logo

AngioDynamics Inc (ANGO)

Upturn stock ratingUpturn stock rating
$10.13
Last Close (24-hour delay)
Profit since last BUY1.2%
upturn advisory
Consider higher Upturn Star rating
BUY since 2 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: ANGO (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $18.25

1 Year Target Price $18.25

Analysts Price Target For last 52 week
$18.25 Target price
52w Low $5.83
Current$10.13
52w High $13.5

Analysis of Past Performance

Type Stock
Historic Profit -34.74%
Avg. Invested days 23
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 411.62M USD
Price to earnings Ratio -
1Y Target Price 18.25
Price to earnings Ratio -
1Y Target Price 18.25
Volume (30-day avg) 3
Beta 0.67
52 Weeks Range 5.83 - 13.50
Updated Date 08/28/2025
52 Weeks Range 5.83 - 13.50
Updated Date 08/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.83

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -11.62%
Operating Margin (TTM) -4.53%

Management Effectiveness

Return on Assets (TTM) -5.03%
Return on Equity (TTM) -17.5%

Valuation

Trailing PE -
Forward PE 96.15
Enterprise Value 371861255
Price to Sales(TTM) 1.41
Enterprise Value 371861255
Price to Sales(TTM) 1.41
Enterprise Value to Revenue 1.27
Enterprise Value to EBITDA 213.96
Shares Outstanding 40633900
Shares Floating 31380330
Shares Outstanding 40633900
Shares Floating 31380330
Percent Insiders 6.84
Percent Institutions 93.84

ai summary icon Upturn AI SWOT

AngioDynamics Inc

stock logo

Company Overview

overview logo History and Background

AngioDynamics, Inc. was founded in 1988. It develops, manufactures, and markets a wide range of medical devices used by interventional radiologists, surgeons, and other physicians for vascular access, peripheral vascular disease, and oncology.

business area logo Core Business Areas

  • Vascular Interventions and Therapies: Focuses on products for peripheral vascular disease, thrombus management, and venous disease. Products include angioplasty balloons, stents, thrombolytic catheters, and venous ablation systems.
  • Oncology: Focuses on products for the treatment of liver cancer, kidney cancer, and other cancers. Products include radiofrequency ablation (RFA) systems, microwave ablation (MWA) systems, and irreversible electroporation (IRE) systems.
  • Vascular Access: Focuses on products for providing access to the vascular system for infusion therapy, blood sampling, and other procedures. Products include peripherally inserted central catheters (PICCs), central venous catheters (CVCs), and ports.

leadership logo Leadership and Structure

The leadership team is headed by Jim Clemmer as President and CEO. The organizational structure includes departments for research and development, manufacturing, sales and marketing, finance, and operations.

Top Products and Market Share

overview logo Key Offerings

  • NanoKnife System (IRE): Irreversible Electroporation technology for ablation of soft tissue tumors. Market share information is not readily available, but competitors include Medtronic, Boston Scientific, and Johnson & Johnson in the ablation space. Revenue is not broken out specifically but is part of the Oncology division.
  • BioFlo PICCs: Peripherally inserted central catheters with BioFlo technology designed to resist thrombus accumulation. Market share information for specific PICC brands is not publicly available. Competitors include Becton Dickinson (BD) and Teleflex.
  • AngioVac System: A mechanical thrombectomy system designed to remove thrombi or emboli from large vessels. Competitors include Penumbra and Inari Medical.

Market Dynamics

industry overview logo Industry Overview

The medical device industry is characterized by technological advancements, increasing regulatory scrutiny, and consolidation. Demand is driven by an aging population and increasing prevalence of chronic diseases.

Positioning

AngioDynamics holds a niche position, focusing on specific areas within interventional radiology and vascular surgery. They compete with larger players in certain markets but also have unique product offerings.

Total Addressable Market (TAM)

The global medical device market is estimated to be hundreds of billions of dollars. AngioDynamics participates in specific segments within vascular access, peripheral vascular intervention, and oncology. Their positioning allows them to address a significant portion of this TAM.

Upturn SWOT Analysis

Strengths

  • Proprietary technologies like NanoKnife
  • Established distribution network
  • Focus on niche markets
  • Experienced management team

Weaknesses

  • Smaller market capitalization compared to major competitors
  • Reliance on a limited number of key products
  • Vulnerable to changes in reimbursement policies
  • Product recalls can significantly impact the company.

Opportunities

  • Expanding product portfolio through acquisitions
  • Growing demand for minimally invasive procedures
  • Entering new geographic markets
  • Strategic partnerships with other medical device companies

Threats

  • Intense competition from larger companies
  • Technological obsolescence
  • Increasing regulatory hurdles
  • Economic downturns affecting hospital budgets

Competitors and Market Share

competitor logo Key Competitors

  • MDT
  • BSX
  • JNJ
  • BDX
  • TFX
  • INMD

Competitive Landscape

AngioDynamics competes with larger, more established companies. Their strengths lie in niche markets and proprietary technologies. They must continue to innovate and execute effectively to maintain their competitive position.

Major Acquisitions

Athea Vascular

  • Year: 2022
  • Acquisition Price (USD millions): 18.5
  • Strategic Rationale: Athea Vascular strengthens AngioDynamics' existing thrombus management portfolio, including its AlphaVac F188 System.

Growth Trajectory and Initiatives

Historical Growth: Historical growth relies on financial documentation.

Future Projections: Future projections are based on third-party analyst estimates.

Recent Initiatives: Recent initiatives include product development, acquisitions, and strategic partnerships. These should be identified through press releases and investor relations materials.

Summary

AngioDynamics is a niche player in the medical device industry with innovative technologies like NanoKnife. The company is smaller compared to its key competitors but has growth potential through strategic acquisitions and expansion into new markets. The company's reliance on key products and its vulnerability to reimbursement changes remain a concern. AngioDynamics needs to improve scalability and focus on marketing to increase sales across the board.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings
  • Company Website
  • Analyst Reports
  • Press Releases

Disclaimers:

This information is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source. Financial data should be verified with the company's official filings.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About AngioDynamics Inc

Exchange NASDAQ
Headquaters Latham, NY, United States
IPO Launch date 2004-05-27
CEO, President & Director Mr. James C. Clemmer
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 675
Full time employees 675

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.